Sweden's XVIVO Q3 revenue beat expectations on thoracic sales

By Reuters News


Overview

  • Sweden medical technology firm's Q3 sales rose 34% yr/yr, beating analyst expectations

  • Adjusted EPS for Q3 rose to SEK 1.42, no analyst estimate provided

  • Company received CE certificate for Heart Assist Transport System and advanced clinical trials


Outlook

  • Company did not provide specific financial guidance for the current or coming periods in the press release


Result Drivers

  • THORACIC SALES - Co said thoracic sales increased by 51% in local currencies, helping drive overall growth

  • ABDOMINAL SALES - Co reported abdominal sales rose 12% in local currencies

  • SERVICE SALES DECLINE - Co said services sales decreased by 28% in local currencies, partially offsetting growth in other segments


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Beat

SEK 252.60 mln

SEK 234.38 mln (4 Analysts)

Q3 EPS

SEK 1.42

Q3 Net Income

SEK 44.60 mln

Q3 EBIT

SEK 28 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Xvivo Perfusion AB is SEK330.00, about 45.6% above its October 21 closing price of SEK226.60

  • The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 52 three months ago


Reuters Recommended Reads

  • Oct 22 - Sweden's Arjo Q3 revenue beats estimates, gross margin expands

  • Oct 22 - Sweden's Sedana Medical Q3 sales rise as growth returns

  • Oct 21 - Medical gear maker Getinge beats Q3 profit estimates on pricing, product mix


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.